Chromatography Beads with Thin Outer Layer for Virus Removal

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for virus removal during monoclonal antibody purification are inadequate, requiring improved technologies to effectively capture and remove viruses from immunoglobulin-containing samples while maintaining high binding capacity and selectivity.

Innovation Solution

The use of chromatography beads with a thin, inactive outer layer and a core functionalized with affinity ligands, such as Protein A or Protein L, which allows for the selective adsorption of monoclonal antibodies while preventing virus penetration, thereby achieving efficient virus removal and purification.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional virus removal filters with defined cut-off are used, then virus removal is achieved, but binding capacity and selectivity for monoclonal antibodies are compromised

Engineering Contradiction:
Improvevirus removal efficiencyVSAvoidbinding capacity for mAbs
Core Design Contradiction:
ReliabilityVSQuantity of substance

Solution Approach 1:

The chromatography bead is segmented into two distinct functional zones: an outer inactive layer with defined pore size for virus exclusion, and an inner core functionalized with affinity ligands (Protein A or Protein L) for selective mAb binding. This segmentation allows simultaneous virus removal and maintained binding capacity without compromise.

Inventive Principle:
Principle #1Segmentation

2Quantity of substance

If chromatography beads with affinity ligands are used for mAb purification, then binding capacity is improved, but virus penetration and contamination risk increase

Engineering Contradiction:
Improvebinding capacity for mAbsVSAvoidvirus penetration
Core Design Contradiction:
Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The inactive outer layer acts as an intermediary barrier between the virus-containing feed and the affinity ligands in the core. This layer has defined pore size that physically blocks virus penetration while allowing mAbs to reach the ligands through diffusion, thus protecting against virus contamination while maintaining binding capacity.

Inventive Principle:
Principle #24Intermediary (Mediator)

3Quantity of substance

If chromatography beads with thin outer layer are used, then binding capacity is maintained, but virus exclusion capability is reduced

Engineering Contradiction:
Improvebinding capacityVSAvoidvirus exclusion capability
Core Design Contradiction:
Quantity of substanceVSReliability

Solution Approach 1:

The inactive outer layer is designed as a thin film with controlled thickness (1-10 μm) that balances two opposing requirements: thin enough to allow rapid mAb diffusion and maintain high binding capacity, yet with defined pore size structure that provides reliable physical exclusion of viruses. The film's porosity and thickness are optimized to achieve both goals simultaneously.

Inventive Principle:
Principle #30Flexible shells and thin films

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This method provides enhanced virus reduction capabilities compared to prior art methods, simplifying downstream processing and ensuring the production of virus-free therapeutic antibodies, as demonstrated by improved log reduction and yield in experimental trials.

Implementation Method 1

an inner core of defined pore size provided with an affinity ligand; adsorbing the immunoglobulin containing proteins to the ligands

Methodology Applied
Scientific EffectAffinity adsorption: Adsorption

Implementation Method 2

a thin lid with a defined pore size and an inner core of defined pore size provided with an affinity ligand

Methodology Applied
Scientific EffectPhysical filtration: Filter (physical)

Data Source

PatentUS11053283B2Chromatography method
Publication Date: 2021.07.06 CYTIVA BIOPROCESS R&D AB
  • US11053283B2 patent drawing
  • US11053283B2 patent drawing
  • US11053283B2 patent drawing

AI summary

The present invention relates to a method for removal of large contaminants, such as virus, in a chromatographic process for purification of a target molecule, preferably monoclonal antibodies, mAbs, by using a specifically designed chromatographic bead having a thin outer layer and a core functionalized with a ligand adsorbing the mAbs or parts thereof.